Last reviewed · How we verify
Cobefrin — Competitive Intelligence Brief
unknown
nordefrin
Adrenergic receptor alpha-2
Neuroscience
Live · refreshed every 30 min
Target snapshot
Cobefrin (nordefrin). Cobefrin works by stimulating the sympathetic nervous system to increase the levels of certain neurotransmitters.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cobefrin TARGET | nordefrin | unknown | nordefrin | Adrenergic receptor alpha-2 | ||
| Aldomet | METHYLDOPATE | Merck & Co. | marketed | Adrenergic receptor alpha-2 | 1962-01-01 | |
| Levonordefrin | corbadrine | Eastman Kodak | marketed | corbadrine | Alpha-1D adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1 | 1960-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (nordefrin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cobefrin CI watch — RSS
- Cobefrin CI watch — Atom
- Cobefrin CI watch — JSON
- Cobefrin alone — RSS
- Whole nordefrin class — RSS
Cite this brief
Drug Landscape (2026). Cobefrin — Competitive Intelligence Brief. https://druglandscape.com/ci/nordefrin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing